MaxCyte’s CEO explains the various ways CGT is impacted by new technologies and methods of treatment delivery.
Maher Masoud
Advertisement
Maher Masoud is CEO of MaxCyte.
Articles by Maher Masoud
Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry.
MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.
Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Marty Makary Out as FDA Commissioner: Report
3
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
4
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
5